Short answer
Bio-rad Laboratories Inc (BIO) filed its Q1 2017 10-Q quarterly report on May 9, 2017 for the quarter ended Mar 31, 2017.
Bio-rad Laboratories Inc Q1 2017 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q1 revenue $500.1M, up 6.1% YoY from $471.2M, currency-neutral growth 6.7%
- Clinical Diagnostics strongest segment, sales $322.3M, up 6.8% YoY, versus Life Science sales $174.3M, up 5.1%
- Gross margin 54.0% vs 56.0% YoY, net margin 2.5% vs 2.6%
- Operating cash flow used $56.2M vs $7.4M, capital expenditures $39.3M vs $25.3M
- Cash, equivalents and short-term investments $674.1M; RainDance acquisition cash payments $72.9M and $10.0M one-time expense
Risk Factors
- New regulatory risk: European conflict-minerals regulation approved March-April 2017, effective January 2021
- Updated ERP risk: Western Europe deployment launched April 2017, with greater complexity than prior deployments
- Regulatory exposure: European in-vitro diagnostic rules approved April 2017, adding stricter labeling requirements
- Operational risk: 63% of first-quarter net sales generated by foreign subsidiaries
- Financial risk: $434.8 million outstanding debt as of March 31, 2017
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bio-rad Laboratories Inc quarterly reports
- Q3 2019 10-QFiled Nov 1, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 10, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 9, 2018
- Q1 2018 10-QFiled May 10, 2018
- Q3 2017 10-QFiled Nov 9, 2017
- Q2 2017 10-QFiled Aug 7, 2017
- Q3 2016 10-QFiled Nov 2, 2016
- Q2 2016 10-QFiled Aug 5, 2016
- Q1 2016 10-QFiled May 6, 2016
- Q3 2015 10-QFiled Nov 5, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.